title: Hypereosinophilic syndrome treated with alpha-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity.
abstract: A 34-year-old male with hypereosinophilic syndrome (HES) and cardiac complications was treated with recombinant human alpha-interferon (rhIFN) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the attempt to suppress the eosinophilic cell clones and stimulate the neutrophil myelopoiesis in the bone marrow, respectively. After 1 month of pretreatment with rhIFN, rhG-CSF was administered daily for 22 days. Within a few days the combined treatment with rhIFN and rhG-CSF was followed by a marked increase in absolute neutrophil count but complicated by abdominal pain and an increase in plasma creatinine and blood urea nitrogen. The renal failure persisted when rhIFN therapy was stopped but resolved after discontinuing rhG-CSF. The pathogenesis of this reversible renal involvement needs further investigation. In that hematological improvement in vivo as well as in vitro followed the administration of rhIFN and rhG-CSF, a role for combined therapy with these cytokines may be advocated. However, caution with regard to kidney function should be taken with this combination therapy.
authors.affiliation: Department of Hematology L, University of Copenhagen, Herlev Hospital, Denmark.
authors.forename: P B
authors.initials: PB
authors.lastname: Hansen
authors.forename: H E
authors.initials: HE
authors.lastname: Johnsen
authors.forename: E
authors.initials: E
authors.lastname: Hippe
mesh_terms: D000328:Adult; D001806:Blood Urea Nitrogen; D001853:Bone Marrow / Q000473:pathology; D003404:Creatinine / Q000097:blood; D004802:Eosinophilia / Q000097:blood / Q000473:pathology / Q000628:therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013577:Syndrome
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003404:Creatinine